Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 5, 2012, Pages 578-587

  Cutler, D L ^a   Tendolkar, A ^a   Grachev, I D ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GE HEALTHCARE   (United States)

Author keywords

healthy subjects; MK 3814; Parkinson's disease; pharmacokinetics; preladenant; SCH420814

Indexed keywords

DRUG METABOLITE; PLACEBO; PRELADENANT; SCH 434748; SCH 446637; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE CUFF; BLOOD PRESSURE FLUCTUATION; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FLUSHING; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SWEATING; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 84865862583     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01349.x     Document Type: Article

References (22)

1. de Lau LML, Breteler MMB,. Epidemiology of Parkinson's disease. Lancet Neurol, 2006; 5: 525-535.
2. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci, 1997; 18: 338-344. (Pubitemid 27404661)
3. Stacy M,. Medical treatment of Parkinson disease. Neurol Clin, 2009; 27: 605-631.
4. Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, et al. Mov Disord, 2008; 23: S548-S559.
5. Alexander GE, Crutcher MD,. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci, 1990; 13: 266-271. (Pubitemid 20193456)
6. 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord, 2009; 15: 406-413.
7. 2A receptors and basal ganglia physiology. Prog Neurobiol, 2007; 83: 277-292. (Pubitemid 350110609)
8. Hettinger BD, Lee A, Linden J, Rosin DL,. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol, 2001; 431: 331-346. (Pubitemid 32115298)
9. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discove, 2007; 2: 1-21. (Pubitemid 46729088)
10. Dayne MR, Larson G, Orona RA, Zahniser NR,. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse, 1996; 22: 132-138.
11. 2A antagonists. Neurology, 2003; 61: S44-S48. (Pubitemid 37505546)
12. Lundblad M, Vaudano E, Cenci MA,. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem, 2003; 84: 1398-1410. (Pubitemid 36343606)
13. Grondin R, Bedard PJ, Hadj TA, Gregoire L, Mori A, Kase H,. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology, 1999; 52: 1673-1677. (Pubitemid 29220647)
14. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol, 1998; 43: 507-513. (Pubitemid 28231727)
15. Hodgson RA, Bertorelli R, Varty GB, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-2-furanyl)-7H-pyrazolo[4, 3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther, 2009; 330: 294-303.
16. 2 receptors modulate haloperidol-induced catalepsy in rats. Eur J Pharmacol, 1997; 328: 135-141. (Pubitemid 27263351)
17. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology, 1999; 147: 90-95. (Pubitemid 30010028)
18. Neustadt BR, Hao J, Lindo N, et al. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett, 2007; 17: 1376-1380. (Pubitemid 46240836)
19. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol, 2011; 10: 221-229.
20. 2A adenosine receptors in human peripheral blood cells. Br J Pharmacol, 2000; 129: 2-11. (Pubitemid 30072665)
21. Thomas T, St Lambert JH, Dashwood MR, Spyer KM,. Localization and action of adenosine A2a receptors in regions of the brainstem important in cardiovascular control. Neurosci, 2000; 95: 513-518.
22. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP,. Epidemiology of Parkinson's disease. J Neurol, 2008; 255: 18-32.